RU2501803C2 - Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) - Google Patents

Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) Download PDF

Info

Publication number
RU2501803C2
RU2501803C2 RU2010116994/10A RU2010116994A RU2501803C2 RU 2501803 C2 RU2501803 C2 RU 2501803C2 RU 2010116994/10 A RU2010116994/10 A RU 2010116994/10A RU 2010116994 A RU2010116994 A RU 2010116994A RU 2501803 C2 RU2501803 C2 RU 2501803C2
Authority
RU
Russia
Prior art keywords
oligonucleotide
oligonucleotide according
seq
modified
nucleobase
Prior art date
Application number
RU2010116994/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2010116994A (ru
Inventor
Сэнджей БХАНОТ
Рави ДЖЕЙН
Син-сянь Ю
Сьюзан М. Фрейер
Original Assignee
Айзис Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айзис Фармасьютикалз, Инк. filed Critical Айзис Фармасьютикалз, Инк.
Publication of RU2010116994A publication Critical patent/RU2010116994A/ru
Application granted granted Critical
Publication of RU2501803C2 publication Critical patent/RU2501803C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2010116994/10A 2007-10-01 2008-10-01 Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) RU2501803C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97678207P 2007-10-01 2007-10-01
US60/976,782 2007-10-01
PCT/US2008/078497 WO2009046141A2 (en) 2007-10-01 2008-10-01 Antisense modulation of fibroblast growth factor receptor 4 expression

Publications (2)

Publication Number Publication Date
RU2010116994A RU2010116994A (ru) 2013-01-20
RU2501803C2 true RU2501803C2 (ru) 2013-12-20

Family

ID=40526946

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010116994/10A RU2501803C2 (ru) 2007-10-01 2008-10-01 Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4)

Country Status (13)

Country Link
US (2) US8486904B2 (enExample)
EP (1) EP2215102B1 (enExample)
JP (1) JP5792955B2 (enExample)
KR (1) KR101660989B1 (enExample)
CN (1) CN101883777B (enExample)
AU (1) AU2008308691B2 (enExample)
BR (1) BRPI0817527A2 (enExample)
CA (1) CA2701128A1 (enExample)
IL (1) IL204796A (enExample)
MX (1) MX2010003606A (enExample)
NZ (1) NZ584827A (enExample)
RU (1) RU2501803C2 (enExample)
WO (1) WO2009046141A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0817527A2 (pt) 2007-10-01 2017-05-02 Isis Pharmaceuticals Inc modulação antissenso da expressão do receptor de fator de crescimento de fibroblasto humano 4
ES2616051T3 (es) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Método para la síntesis de ácidos nucleicos modificados en el átomo de fósforo
JP2012524068A (ja) * 2009-04-15 2012-10-11 アイシス ファーマシューティカルズ， インコーポレーテッド 第ｘｉ因子による炎症反応のモジュレーション
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2012142458A1 (en) 2011-04-13 2012-10-18 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
AU2012271357A1 (en) 2011-06-16 2013-05-02 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102337247B (zh) * 2011-09-13 2013-07-10 西安交通大学 一种fgfr4高表达的重组hek293细胞及其应用
RS61089B1 (sr) 2012-06-13 2020-12-31 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
MX356830B (es) 2012-07-13 2018-06-15 Shin Nippon Biomedical Laboratories Ltd Adyuvante de acido nucleico quiral.
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
US9982257B2 (en) 2012-07-13 2018-05-29 Wave Life Sciences Ltd. Chiral control
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
AR092982A1 (es) * 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
NZ708171A (en) 2012-11-15 2019-11-29 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MX2015009056A (es) 2013-01-30 2015-10-05 Hoffmann La Roche Conjugados de oligonucleotidos de acido nucleico bloqueado y carbohidratos.
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
BR112015027319A8 (pt) 2013-05-01 2018-01-02 Isis Pharmaceuticals Inc Métodos e composições para modular a expressão de apolipoproteína (a)
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
DK3094728T3 (da) 2014-01-16 2022-05-16 Wave Life Sciences Ltd Kiralt design
SMT202100562T1 (it) 2014-03-19 2021-11-12 Ionis Pharmaceuticals Inc Composizioni per modulare l'espressione di ataxina 2
WO2015143245A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Methods for modulating ataxin 2 expression
CN110903337A (zh) 2014-05-01 2020-03-24 Ionis制药公司 用于调节生长激素受体表达的组合物和方法
WO2015179693A1 (en) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
DK3320094T3 (da) * 2015-07-10 2022-05-23 Ionis Pharmaceuticals Inc Modulatorer af diacyglycerol-acyltransferase 2 (dgat2)
WO2017117496A1 (en) 2015-12-31 2017-07-06 Ionis Pharmaceuticals, Inc. Methods for reducing ataxin-2 expression
EP3522898A4 (en) 2016-10-06 2020-05-27 Ionis Pharmaceuticals, Inc. METHOD FOR CONJUGATING OLIGOMERIC COMPOUNDS
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR20210018264A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 염
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
SG11202100077PA (en) 2018-07-25 2021-02-25 Ionis Pharmaceuticals Inc Compounds and methods for reducing atxn2 expression
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN112759593A (zh) 2019-11-01 2021-05-07 北京伯汇生物技术有限公司 桥环并醛基吡啶衍生物及其应用
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003179A1 (en) * 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
US20050246794A1 (en) * 2002-11-14 2005-11-03 Dharmacon Inc. Functional and hyperfunctional siRNA

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420081A1 (en) 1989-09-26 1991-04-03 Takeda Chemical Industries, Ltd. Monoclonal antibody against an acidic FGF protein, its production and use
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US20040006005A1 (en) * 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
CA2152903A1 (en) * 1992-12-31 1994-07-21 Larry A. Denner Antisense molecules directed against a fibroblast growth factor receptor gene family
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
WO2001018210A1 (en) 1999-09-08 2001-03-15 Genentech, Inc. Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
ATE212552T1 (de) 1998-04-17 2002-02-15 Tufts College Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US6153432A (en) 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
US6136603A (en) * 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
ATE318603T1 (de) 1999-05-21 2006-03-15 Bristol Myers Squibb Co Pyrrolotriazin kinasehemmer
AU2631001A (en) 2000-01-05 2001-07-16 Zymogenetics Inc. Novel fgf homolog zfgf11
US6261840B1 (en) * 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US6159734A (en) * 2000-01-18 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of peroxisome proliferator-activated receptor gamma expression
CA2403572A1 (en) 2000-03-22 2001-09-27 Amgen Inc. Fibroblast growth factor receptor-like molecules and uses thereof
WO2001072957A2 (en) 2000-03-31 2001-10-04 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
EP1318833A2 (en) 2000-05-12 2003-06-18 The University of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
EP1202065A1 (en) 2000-10-25 2002-05-02 Aventis Pharma S.A. Net, a transcription factor of the TCF family, as regulator of angiogenic expression.
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
DE10152147A1 (de) 2001-10-25 2003-05-15 Chemogenix Gmbh Verfahren zum Aufbringen von Nukleosiden und/oder Nukleotiden auf funktionalisierten Oberflächen sowie Verfahren zur Bestimmung von Kopplungsausbeuten bei der Synthese von Nukleotiden
EP1441725A1 (en) 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
US7655397B2 (en) * 2002-04-25 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
DE60317198T2 (de) 2002-05-23 2008-12-04 Cytopia Research Pty. Ltd., Richmond Proteinkinaseinhibitoren
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
KR101016250B1 (ko) 2002-07-08 2011-02-25 코닌클리즈케 필립스 일렉트로닉스 엔.브이. 반사형 디스플레이 및 이를 포함하는 휴대형 장치
AU2003286757B2 (en) 2002-11-01 2009-06-04 Merck Sharp & Dohme Corp. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
US7803781B2 (en) * 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20050048494A1 (en) 2003-08-28 2005-03-03 Yixin Wang Colorectal cancer prognostics
ATE506077T1 (de) * 2003-10-16 2011-05-15 Imclone Llc Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür
CA2550245A1 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
CA2555335A1 (en) * 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
EP1713819A4 (en) * 2004-02-05 2007-11-14 Intradigm Corp METHOD AND COMPOSITIONS FOR COMBINING RNAI THERAPEUTICS
US7374927B2 (en) * 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
US20060286102A1 (en) * 2004-05-14 2006-12-21 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
US20090036355A1 (en) * 2004-10-13 2009-02-05 Sanjay Bhanot Antisense Modulation of PTP1B Expression
CA2630974A1 (en) * 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
US20100105134A1 (en) * 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
BRPI0817527A2 (pt) 2007-10-01 2017-05-02 Isis Pharmaceuticals Inc modulação antissenso da expressão do receptor de fator de crescimento de fibroblasto humano 4

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003179A1 (en) * 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
US20050246794A1 (en) * 2002-11-14 2005-11-03 Dharmacon Inc. Functional and hyperfunctional siRNA

Also Published As

Publication number Publication date
WO2009046141A2 (en) 2009-04-09
KR20100081994A (ko) 2010-07-15
BRPI0817527A2 (pt) 2017-05-02
CN101883777B (zh) 2015-03-25
RU2010116994A (ru) 2013-01-20
JP5792955B2 (ja) 2015-10-14
NZ584827A (en) 2012-10-26
AU2008308691A1 (en) 2009-04-09
IL204796A (en) 2014-04-30
EP2215102B1 (en) 2016-02-17
AU2008308691B2 (en) 2013-11-07
US20140080892A1 (en) 2014-03-20
MX2010003606A (es) 2010-07-02
CN101883777A (zh) 2010-11-10
JP2010539950A (ja) 2010-12-24
KR101660989B1 (ko) 2016-09-28
HK1146726A1 (zh) 2011-07-08
EP2215102A4 (en) 2012-04-11
IL204796A0 (en) 2010-11-30
US8895529B2 (en) 2014-11-25
CA2701128A1 (en) 2009-04-09
US20100292140A1 (en) 2010-11-18
WO2009046141A3 (en) 2009-05-28
EP2215102A2 (en) 2010-08-11
US8486904B2 (en) 2013-07-16

Similar Documents

Publication Publication Date Title
RU2501803C2 (ru) Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4)
US20230210887A1 (en) Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection
JP2010539950A5 (enExample)
JP2012050438A5 (enExample)
JP2009508527A5 (enExample)
JP2016522817A5 (enExample)
JP2019014733A (ja) Ｔｎｆスーパーファミリー受容体に対するスプライス切替オリゴマーならびに疾病治療における該オリゴマーの使用
JP2024091781A (ja) Ｓｃｎ１ａ脳症の治療のためのｓｃｎ２ａを標的とするアンチセンスオリゴヌクレオチド
JP2012508560A5 (enExample)
JP2011504362A5 (enExample)
JP6326433B2 (ja) 三環式ヌクレオシド及びそれから調製されるオリゴマー化合物
IL300119A (en) Oligonucleotides to induce paternal UBE3A expression
JP2015504650A5 (enExample)
JP2016502858A5 (enExample)
JP2003523739A5 (enExample)
JP2012029693A5 (enExample)
JP2019088329A5 (enExample)
CA2520541A1 (en) Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field
JP2021072862A (ja) Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子
JP2016523548A5 (enExample)
CN108410868A (zh) Gcgr表达的反义调节
KR20150004414A (ko) Kras-관련 질환을 치료하기 위한 유기 조성물
TW202006138A (zh) Fubp1抑制劑用於治療b型肝炎病毒感染之用途
RU2016102833A (ru) Модуляторы рецептора гормона роста
JP2006141402A5 (enExample)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20171002